39 research outputs found
Relazioni tra prestazione visiva, abilità motoria e attività fisica in soggetti in età scolare
No full textL'attività fisica garantisce benefici relativi allo stato di salute e agli aspetti comportamentali (Strong et al., 2005; Marcus et al., 2006; Physical Activity Guidelines Advisory Committee, 2008), mentre l’assenza di movimento può portare a un decremento della qualità della vita e
a un aumento di patologie gravi e mortalità (Kaplan et al., 1987; Grand et al., 1990; Lynch et al., 2008).
Durante l’infanzia avviene l’apprendimento degli schemi motori di base che rappresentano l’espressione del movimento e vengono considerati la base per la creazione del movimento specializzato (Gallahue & Ozmun, 2006; Clark & Metcalfe, 2002). In particolare, negli ultimi anni, è stata studiata la coordinazione motoria in associazione con la quantità di attività fisica svolta e la maggior parte degli Autori hanno riscontrato una relazione (Graf et al., 2014; Fisher et al., 2005; Castelli & Valley, 2007; Erwin & Castelli, 2008).
Nel presente studio sono state valutate anche le abilità visive, poiché è dimostrato come problematiche visive nei soggetti tendano a essere correlate con una minor pratica di attività sportiva (Kozub & Oh, 2004). L’obiettivo dell’evidenza era quello di analizzare i valori di performance visivi e motori e la loro relazione con la tipologia e la quantità di attività fisica praticata in soggetti in età scolare
Visual and Motor Capabilities of Future Car Drivers
No full textDriving safety is recognized as critical for young people by institu-tions, insurances and research. The ability to manage such a complex activity as driving is still developing through adolescence and in early adulthood. The present research investigates the human factors in the driver-car interaction. The experimental method assesses the visual-motor coordination capabilities of future drivers, also in relation to their life styles. The results show that a frequent but good quality physical activity improves visual-motor coordina-tion
Au nanoparticles decorated nanographene oxide-based platform: Synthesis, functionalization and assessment of photothermal activity
No full textA novel hybrid nanocomposite formed of carboxylated Nano Graphene Oxide (c-NGO), highly densely decorated by monodisperse citrate-coated Au nanoparticles (c-NGO/Au NPs), is synthesized and thoroughly characterized for photothermal applications. A systematic investigation of the role played by the synthetic parameters on the Au NPs decoration of the c-NGO platform is performed, comprehensively studying spectroscopic and morphological characteristics of the achieved nanostructures, thus elucidating their still not univocally explained synthesis mechanism. Remarkably, the Au NPs coating density of the c-NGO sheets is much higher than state-of-the-art systems with analogous composition prepared with different approaches, along with a higher NPs size dispersion. A novel theoretical approach for estimating the average number of NPs per sheet, combining DLS and TEM results, is developed. The assessment of the c-NGO/Au NPs photothermal activity is performed under continuous wave (CW) laser irradiation, at 532 nm and 800 nm, before and after functionalization with PEG-SH. c-NGO/Au NPs composite behaves as efficient photothermal agent, with a light into heat conversion ability higher than that of the single components. The c-NGO/Au NPs compatibility for photothermal therapy is assessed by in vitro cell viability tests, which show no significant effects of c-NGO/Au NPs, as neat and PEGylated, on cell metabolic activity under the investigated conditions. These results demonstrate the great potential held by the prepared hybrid nanocomposite for photothermal conversion technologies, indicating it as particularly promising platform for photothermal ablation of cancer cells
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma
No full textPurpose: The aim of the present study was to evaluate the effects of piroxicam, a widely used nonsteroidal anti-inflammatory drug, alone and in combination with cisplatin (CDDP), on cell growth of mesothelioma cells. Experimental Design: Cell proliferation, cell cycle analysis, and microarray technology were done on MSTO-211H and NCI-H2452 cells treated with piroxicam. Moreover, the effects of piroxicam and CDDP on tumor growth and survival of mouse xenograft models of mesothelioma were determined. Results: Piroxicam treatment of MSTO-211H and NCI-H2452 cells resulted in a significant inhibition of proliferation. Cell cycle analysis revealed that there was an increase in the rate of apoptosis in MSTO-211H cells and an increase in the cells accumulating in G 2-M in NCI-H2452. Moreover, a marked tumor growth inhibition and an extended survival of mice treated with a combination of piroxicam and CDDP in MSTO-211H cell - induced peritoneal mesotheliomas was observed. Last, GeneChip array analysis of MSTO-211H mesothelioma cell line revealed that piroxicam treatment caused up-regulation of metabolic pathway - associated genes and down-regulation of genes related to RNA processing apparatus. Of note, epidermal growth factor receptor, one of the new biological targets of chemotherapy for mesothelioma, was down-regulated and HtrA1, a serine protease recently shown to be an endogenous mediator of CDDP cytotoxicity, was up-regulated following piroxicam treatment both in vitro and in vivo. Conclusion: These data suggest that piroxicam sensitizes mesothelioma cells to CDDP-induced cytotoxicity by modulating the expression of several target genes. Therefore, piroxicam in combination with CDDP might potentially be useful in the treatment of patients with mesothelioma. © 2006 American Association for Cancer Research
Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells
No full textAntiestrogens used for breast cancer (BC) treatment differ among each other for the ability to affect estrogen
receptor (ER) activity and thereby inhibit hormone-responsive cell functions and viability. We used high-density cDNA
microarrays for a comprehensive definition of the gene pathways affected by 17b-estradiol (E2), ICI 182,780 (ICI), 4OHtamoxifen
(Tamoxifen), and raloxifene (RAL) in ER-positive ZR-75.1 cells, a suitable model to investigate estrogen and
antiestrogen actions in hormone-responsive BC. The expression of 601 geneswas significantly affected by E2 in these cells; in
silico analysis reveals that 86 among theminclude one ormore potential ER binding sitewithin or near the promoter and that
the binding site signatures for E2F-1, NF-Y, and NRF-1 transcription factors are significantly enriched in the promoters of
genes induced by estrogen treatment, while those for CAC-binding protein and LF-A1 in those repressed by the hormone,
pointing to novel transcriptional effectors of secondary responses to estrogen in BC cells. Interestingly, expression of 176 E2-
regulated mRNAs was unaffected by any of the antiestrogens tested, despite the fact that under the same conditions the
transcriptional and cell cycle stimulatory activities of ER were inhibited.On the other hand, of 373 antiestrogen-responsive
genes identifiedhere,52wereunresponsive to estrogen and 25%respondedspecifically toonlyoneof thecompounds tested,
revealing non-overlapping and clearly distinguishable effects of the different antiestrogens in BC cells. As some of these
differences reflect specificities of themechanismof action of the antiestrogens tested, we propose to exploit this gene set for
characterization of novel hormonal antagonists and selective estrogen receptor modulators (SERMs) and as a tool for testing
newassociations of antiestrogens,more effective against BC
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
No full textRat sarcoma (RAS) oncogenes have intensively been investigated during the last decades. Taking into account all human tumours, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene is the most frequently mutated (about 22%) among the three isoforms, followed by Neuroblastoma RAS Viral Oncogene Homolog (NRAS) (8%) and Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) (3%). In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients because of their prognostic and predictive roles. In particular, a large body of literature data has been generated investigating clinical outcomes of targeted treatments in NSCLC and CRC KRAS- and NRAS-mutated patients. The latest evidences are here reviewed, providing also an overview of the real-world RAS mutation testing practice across different Italian laboratories. On this basis, we propose a knowledge-based system, www.rasatlas.com, to support the healthcare personnel in the management of patients featuring RAS gene mutations in the landscape of precision oncology
Author response: Functionally diverse human T cells recognize non-microbial antigens presented by MR1
No full textChanges in lipid profile and adipokine levels in GH deficient children during GH replacement therapy.
No full textLow hrTSH-Tg levels in patients affected by papillary thyroid microcarcinoma are influenced by pre-surgery L-thyroxine therapy.
No full textCorrection to: Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research
Get PDFIn the original publication of the article, the author name has been incorrectly published as Maria C. Santagati in the Review (2022). The correct name is Maria Santagati. The original article has been corrected
